Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the European Commission as an add-on treatment to standard-of-care therapies ravulizumab (Ultomiris) or eculizumab (Soliris) for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who suffer from residual haemolytic anaemia. This approval marks a significant advancement for the approximately […]